Jazz Pharmaceuticals JAZZ reported third-quarter 2025 adjusted earnings per share (EPS) of $8.13 per share, beating the Zacks Consensus Estimate of $5.74. This beat was largely due to an income tax ...
Jazz Pharmaceuticals reported a 37.1% EPS surprise, beating market expectations. Revenue grew by 7% year-over-year, driven by strong product sales. Stock declined 0.44% in after-hours trading despite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results